More importantly, the strategy of targeting YAP1 to drive CAF phenotype switching from pro-tumor to anti-tumor offers a highly attractive new avenue for overcoming the immunosuppressive TME in PCa and improving immunotherapy response. Here, YAP1 is linked to neoplasm.